| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Biosimilar rhG-CSFs: how similar are they?
|
Gravel, Patricia
|
|
2012
|
|
supplement-1 |
p. 3-16
|
article
|
| 2 |
Biosimilars: Is absence of proof of difference, proof of absence of difference?
|
Dicato, M.
|
|
2011
|
|
supplement-1 |
p. 1-2
|
article
|
| 3 |
Colony stimulating factors (CSF) biosimilars. Progress?
|
Scotté, Florian
|
|
2012
|
|
supplement-1 |
p. 17-24
|
article
|
| 4 |
Erythropoietin biosimilars currently available in hematology-oncology
|
Kamioner, Didier
|
|
2012
|
|
supplement-1 |
p. 25-28
|
article
|
| 5 |
Low molecular weight heparin biosimilars: how much similarity for how much clinical benefit?
|
Drouet, Ludovic
|
|
2012
|
|
supplement-1 |
p. 35-42
|
article
|
| 6 |
Presently available biosimilars in hematology-oncology: G-CSF
|
Gascon, Pere
|
|
2012
|
|
supplement-1 |
p. 29-34
|
article
|
| 7 |
Risk management of biosimilars in oncology: each medicine is a work in progress
|
Vulto, Arnold G.
|
|
2012
|
|
supplement-1 |
p. 43-49
|
article
|
| 8 |
The economic pressures for biosimilar drug use in cancer medicine
|
Cornes, Paul
|
|
2012
|
|
supplement-1 |
p. 57-67
|
article
|
| 9 |
What do prescribers think of biosimilars?
|
Aapro, M. S.
|
|
2011
|
|
supplement-1 |
p. 51-55
|
article
|
Journal description